Overview


According to FutureWise analysis the market for amylin analogs in 2023 is US$ 0.58 billion, and is expected to reach US$ 0.9 billion by 2031 at a CAGR of 5.6%.

Diabetes can be treated with amylin analogs. Similar properties are shared by physiological amylin and amylin analogues. Subcutaneous administration of amylin analogs is recommended before eating. These synthetic stable compounds are available in a variety of forms. Pancreatic beta cells secrete amylin and insulin. Amylin, a neuroendocrine hormone containing 37 amino acids and polypeptides, acts as an agent that gives the feeling of fullness or satisfaction. It suppresses food intake, slows gastric emptying, regulates blood sugar with an effect on the renin-angiotensin systems, inhibits glucagon release, and regulates blood pressure. Human amylin can also have metabolic effects. It may also modulate innate inflammation and autoimmunity via regulatory cells. This could impact both type 2 and 1 diabetes. Diabetes is marked by reduced insulin secretion and amylin production. Amylin to Insulin aids in postprandial glucose control. Diabetes patients have a problem with glucose (or sugar) not being converted to energy.

Insufficient insulin production is the reason. Insulin is responsible for glucose transfer from the blood to the cells. Amylin helps regulate glucose appearance. Amylin analogs counter the tendency of human amylin, which tends to aggregate, form insoluble particle and stick to surfaces. These products can help reduce body weight. The global market for amylin analogs is growing due to rising diabetes prevalence in both developed and developing countries. The rise in diabetes prevalence is due to an increase in per capita income, which leads to a more sedentary lifestyle. This is the main cause of diabetes. The global market for amylin analogues is expected to grow during the forecast period due to rising obesity. Amylin analogs are in high demand due to the rising tendency toward physical inactivity. Amylin analogs are driven by diabetes. market's growth. The major driver of the market for amylin analogs is the rising burden of diabetes in industrialised countries around the globe. This is due to their global role and the demand for advanced therapeutic medicines to treat it. The growth rate of amylin analog is also affected by other factors.

Market is also influenced by the increasing healthcare spending, which aids in improving its infrastructure. Moreover, there will be more awareness campaigns by both public and private entities to raise awareness about diabetes and its treatment. market. Market will also grow due to high disposable income and changing lifestyles. market. The market will also grow due to rising geriatric populations and an increase in obesity. The use of e-commerce to replace traditional pharmacies during COVID-19 is expected to increase sales of amylin analogs. An Omni channel strategy allows customers to receive service levels that are beyond their expectations. This will increase the market's growth. Additionally, amylin market growth will be supported by rising investments in advanced technologies and an increase in emerging markets.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Amylin Analogs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Amylin Analogs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • Novo Nordisk A/S
  • Bristol-Myers Squibb Company
  • Biocon

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Diabetes Type

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes

By Drug Type

  • Pramlintide
  • Others

By Dosage

  • Injectables
  • Others

By Route of Administration

  • Subcutaneous 
  • Others

By End-Users

  • Hopitals
  • Specialty Clinics
  • Homecare 
  • Others

By Distribution Channel

  • Hospital pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Amylin Analogs Market By Diabetes Type, By Drug Type, By Dosage, By Route of Administration, By End-Users, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Amylin Analogs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Amylin Analogs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Amylin Analogs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Amylin Analogs Market, By Diabetes Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Type I Diabetes
        2. Type II Diabetes
        3. Gestational Diabetes

  • 8.  Amylin Analogs Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pramlintide
        2. Others

  • 9.  Amylin Analogs Market, By Dosage Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Injectables
        2. Others

  • 10.  Amylin Analogs Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1.Subcutaneous 
        2. Others

  • 11.  Amylin Analogs Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hopitals
        2. Specialty Clinics
        3. Homecare 
        4. Others

  • 12.  Amylin Analogs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others

  • 13.  North America Amylin Analogs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 14.  Latin America Amylin Analogs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 15.  Europe Amylin Analogs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 16.  Asia Pacific Amylin Analogs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 17.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 18.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 19.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AstraZeneca
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Boehringer Ingelheim International GmbH
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Sanofi
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Novo Nordisk A/S
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Bristol-Myers Squibb Company
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Biocon
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview

  • 20.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 21.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients